# A Feasibility Trial to Investigate the Safety and Between-group Effect Size of STIMULAN VG and Standard of Care (SoC) in Participants With Diabetic Foot Osteomyelitis

> **NCT05539963** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Biocomposites Ltd** · enrollment: 61 (actual)

## Conditions studied

- Diabetic Foot Osteomyelitis

## Interventions

- **DRUG:** STIMULAN VG
- **DRUG:** Systemic Antibiotics

## Key facts

- **NCT ID:** NCT05539963
- **Lead sponsor:** Biocomposites Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-01-23
- **Primary completion:** 2025-06-20
- **Final completion:** 2025-12-30
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2025-06-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05539963

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05539963, "A Feasibility Trial to Investigate the Safety and Between-group Effect Size of STIMULAN VG and Standard of Care (SoC) in Participants With Diabetic Foot Osteomyelitis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05539963. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*